NO942299L - Stabilisert, farmasöytisk preparat som omfatter veksthormon og asparagin - Google Patents

Stabilisert, farmasöytisk preparat som omfatter veksthormon og asparagin

Info

Publication number
NO942299L
NO942299L NO942299A NO942299A NO942299L NO 942299 L NO942299 L NO 942299L NO 942299 A NO942299 A NO 942299A NO 942299 A NO942299 A NO 942299A NO 942299 L NO942299 L NO 942299L
Authority
NO
Norway
Prior art keywords
asparagine
growth hormone
pharmaceutical preparation
stabilized pharmaceutical
preparation
Prior art date
Application number
NO942299A
Other languages
English (en)
Norwegian (no)
Other versions
NO942299D0 (no
Inventor
Hans Holmegaard Soerensen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO942299D0 publication Critical patent/NO942299D0/no
Publication of NO942299L publication Critical patent/NO942299L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO942299A 1991-12-20 1994-06-17 Stabilisert, farmasöytisk preparat som omfatter veksthormon og asparagin NO942299L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK912047A DK204791D0 (da) 1991-12-20 1991-12-20 Hidtil ukendt farmaceutisk praeparat
PCT/DK1992/000378 WO1993012811A1 (en) 1991-12-20 1992-12-16 A stabilized pharmaceutical formulation comprising growth hormone and asparagine

Publications (2)

Publication Number Publication Date
NO942299D0 NO942299D0 (no) 1994-06-17
NO942299L true NO942299L (no) 1994-06-17

Family

ID=8109696

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942299A NO942299L (no) 1991-12-20 1994-06-17 Stabilisert, farmasöytisk preparat som omfatter veksthormon og asparagin

Country Status (19)

Country Link
US (2) US5977069A (da)
EP (1) EP0618806B1 (da)
JP (1) JP3662580B2 (da)
KR (1) KR100270726B1 (da)
AT (1) ATE177645T1 (da)
AU (1) AU664416B2 (da)
BG (1) BG98804A (da)
CA (1) CA2125856A1 (da)
CZ (1) CZ282826B6 (da)
DE (1) DE69228704T2 (da)
DK (1) DK204791D0 (da)
FI (1) FI942905A0 (da)
HU (1) HUT69682A (da)
NO (1) NO942299L (da)
NZ (1) NZ246555A (da)
RO (1) RO112086B1 (da)
RU (1) RU2098130C1 (da)
SK (1) SK73794A3 (da)
WO (1) WO1993012811A1 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US5849700A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US6022858A (en) * 1991-12-20 2000-02-08 Novo Nordisk A/S Pharmaceutical formulation of human-growth hormone pretreated with zinc salt
US5849704A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
SE9201073D0 (sv) * 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
US5652216A (en) * 1994-05-26 1997-07-29 Novo Nordisk A/S Pharmaceutical preparation
US5580856A (en) * 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5654278A (en) * 1994-10-13 1997-08-05 Novo Nordisk A/S Composition and method comprising growth hormone and leucine
US5547696A (en) * 1994-10-13 1996-08-20 Novo Nordisk A/S Pharmaceutical formulation
US5631225A (en) * 1994-10-13 1997-05-20 Novo Nordisk A/S Pharmaceutical formulation
ZA96122B (en) * 1995-01-13 1996-07-24 Novo Nordisk As A pharmaceutical formulation
KR19980701351A (ko) * 1995-01-13 1998-05-15 슈타르 피아 성장호르몬 및 Ｘ-Ｌｙｓ를 함유하는 안정화된 약제조제물(A STABILIZED PHARMACEUTICAL FORMULATION COMPRISING A GROWTH HORMONE AND X-Lys
US5705482A (en) * 1995-01-13 1998-01-06 Novo Nordisk A/S Pharmaceutical formulation
US5552385A (en) * 1995-06-05 1996-09-03 Novo Nordisk A/S Pharmaceutical formulation
WO1996040072A2 (en) * 1995-06-07 1996-12-19 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of human growth hormone
ZA965367B (en) * 1995-07-12 1997-01-23 Novo Nordisk As A pharmaceutical formulation
CA2230448A1 (en) * 1995-08-28 1997-03-06 Showa Yakuhin Kako Co., Ltd. Composition for local anesthesia
AUPN801296A0 (en) * 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
US20070179096A1 (en) 1996-04-24 2007-08-02 Novo Nordisk A/S Pharmaceutical Formulation
US20020077461A1 (en) * 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
US6001876A (en) 1996-07-24 1999-12-14 Warner-Lambert Company Isobutylgaba and its derivatives for the treatment of pain
US6696063B1 (en) 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
WO2002011695A2 (en) * 2000-08-07 2002-02-14 Inhale Therapeutic Systems, Inc. Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
US7271150B2 (en) * 2001-05-14 2007-09-18 United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified growth hormone
RU2234945C2 (ru) * 2002-10-15 2004-08-27 Вардосанидзе Ирина Викторовна Стабилизатор водного раствора и водосодержащего сырья с самопроизвольно изменяющимися окислительно-восстановительными свойствами
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
WO2008073856A2 (en) * 2006-12-08 2008-06-19 Massachusetts Institute Of Technology Delivery of nanoparticles and/or agents to cells
US20160015789A1 (en) * 2014-07-17 2016-01-21 Teva Pharmaceutical Industries, Ltd. FORMULATIONS OF AN ALBUMIN hGH FUSION PROTEIN

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
US4917685A (en) * 1986-05-16 1990-04-17 International Minerals & Chem. Corp. Delivery device for the administration of stabilized growth promoting hormones
ATE82506T1 (de) * 1987-08-21 1992-12-15 Imcera Group Inc Stabilisierung von wachstumshormonen.
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
US5122512A (en) * 1988-09-12 1992-06-16 Pitman-Moore, Inc. Swine growth promoting composition
EP0374120A3 (en) * 1988-12-13 1991-07-31 Monsanto Company Comosition for controlled release of polypeptides
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
SK279641B6 (sk) * 1991-12-20 1999-01-11 Novo Nordisk A/S Stabilizovaný farmaceutický prípravok obsahujúci r
SE9201073D0 (sv) * 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
MD1699F2 (ro) * 1992-07-31 2001-07-31 Genentech, Inc. Compoziţie apoasă a hormonului somatotrop uman şi procedeu de prevenire a denaturării ei
US5547696A (en) * 1994-10-13 1996-08-20 Novo Nordisk A/S Pharmaceutical formulation
US5552385A (en) * 1995-06-05 1996-09-03 Novo Nordisk A/S Pharmaceutical formulation

Also Published As

Publication number Publication date
HUT69682A (en) 1995-09-28
FI942905A7 (fi) 1994-06-17
DE69228704D1 (de) 1999-04-22
ATE177645T1 (de) 1999-04-15
RU2098130C1 (ru) 1997-12-10
JPH07502515A (ja) 1995-03-16
NO942299D0 (no) 1994-06-17
AU3344593A (en) 1993-07-28
CZ145894A3 (en) 1994-12-15
DK204791D0 (da) 1991-12-20
FI942905L (fi) 1994-06-17
SK73794A3 (en) 1995-03-08
NZ246555A (en) 1996-03-26
US5851992A (en) 1998-12-22
US5977069A (en) 1999-11-02
BG98804A (bg) 1995-02-28
AU664416B2 (en) 1995-11-16
EP0618806B1 (en) 1999-03-17
RO112086B1 (ro) 1997-05-30
HU9401831D0 (en) 1994-09-28
DE69228704T2 (de) 1999-09-16
RU94045921A (ru) 1996-08-27
CA2125856A1 (en) 1993-07-08
CZ282826B6 (cs) 1997-10-15
JP3662580B2 (ja) 2005-06-22
FI942905A0 (fi) 1994-06-17
WO1993012811A1 (en) 1993-07-08
EP0618806A1 (en) 1994-10-12
KR940703689A (ko) 1994-12-12
KR100270726B1 (ko) 2000-11-01

Similar Documents

Publication Publication Date Title
NO942299D0 (no) Stabilisert, farmasöytisk preparat som omfatter veksthormon og asparagin
NL300126I1 (nl) Gestabiliseerde farmaceutische formulering die groeihormoon en histidine omvat.
KR970706840A (ko) 성장호르몬 및 발린으로 이루어진 약학적 조성물(a pharmaceutical formulation comprising a growth hormone and valine)
IE882671L (en) Stabilised human protein formulation
NO941383L (no) Stabilisering av humant interferon
ATE214614T1 (de) Ein wachstumshormon und isoleucin enthaltende pharmazeutische formulierung
ATE314393T1 (de) Verzögerte freigabe von insulinotropin (glp-1)
DK0658101T3 (da) Aerosolformuleringer fri for overfladeaktivt middel og indeholdende beclomethasondipropionat
ATE21336T1 (de) Galenische form zur oralen verabreichung und verfahren zu deren herstellung.
IT8721538A0 (it) Tiometil e sulfinil metil derivati ad azione antisecretiva acida gastrica, loro procedimento di preparazione e composizioni farmaceutiche che li contengono.
DK0666739T3 (da) Intravenøs opløsning som formindsker protein- og vandtab fra kroppen
NO980103L (no) Stabilisert farmasöytisk preparat som omfatter et veksthormon og et peptid omfattende minst én basisk aminosyrerest og minst én sur aminosyrerest
IL115592A (en) Stabilized pharmaceutical formulation comprising a growth hormone and leucine
JPS5350141A (en) Stabilization of prostaglandin and prostaglandin analogues
DK275979A (da) 1,1,1-trichlorethan stabiliseret mod indvirkning af metaller i naervar af lys og eller oxygenholdige gasser samt fremgangsmaade til stabilisering af 1,1,1-trichlorethan mod saadanne indvirkninger
JPS51143273A (en) Accumulate conveyor
MX9800358A (es) Formulacion farmaceutica estabilizada que comprende una hormona del crecimiento pretratada con zinc y opcionalmente lisina o iones calcio.
BELCHER STABILITY AND CHANGE: PRAISE-POETRY AND NARRATIVE TRADITIONS IN THE EPICS OF MALI (SUNJATA, SEGOU, FULANI)